BioVaxys Technology Corp. announced a delay in filing its audited annual financial statements for the year ended October 31, 2025, missing the February 28, 2026 deadline. The British Columbia Securities Commission issued a management cease trade order (MCTO) on March 3, 2026, restricting the CEO and CFO from trading company securities until filings are completed. BioVaxys is working with auditors to finalize the reports and aims to file by April 28, 2026. The delay also affects interim filings due April 1, 2026, which will be submitted after the annual reports. Despite the MCTO, the public can still trade BioVaxys shares freely. The company remains focused on its clinical-stage biopharmaceutical projects and assures no insolvency proceedings are underway.
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
